报价延迟最少15分钟:2025/08/26 20:30 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
5.87 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-172.70/-0.43
|
|
企业价值
4.69M
|
| 资产负债 |
|
每股账面净值
50.79
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
203.00K
|
|
每股收益
0.81
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟：2025/08/26 20:30 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| NanoVibronix Inc manufactures noninvasive biological response-activating devices that target biofilm prevention, pain therapy, and wound healing and can be administered at home, without the assistance of medical professionals. Its primary products are UroShield; PainShield; and WoundShield. Each of its UroShield, PainShield, and WoundShield products employs a small, disposable transducer that transmits low-frequency, low-intensity ultrasound acoustic waves that seek to repair and regenerate tissue, musculoskeletal and vascular structures, and decrease biofilm formation on urinary catheters and associated urinary tract infections. The company derives revenues from selling its products directly to patients, through distributor agreements. |
